A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

​ Conditions: Pancreatic Cancer

Interventions: Drug: GFH375; Drug: GFH276; Drug: GFS202A

Sponsors: Genfleet Therapeutics (Shanghai) Inc.

Not yet recruiting Conditions: Pancreatic Cancer
Interventions: Drug: GFH375; Drug: GFH276; Drug: GFS202A
Sponsors: Genfleet Therapeutics (Shanghai) Inc.
Not yet recruiting